Sangamo Therapeutics - SGMO Stock Forecast, Price & News

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SGMO shares.
View SGMO analyst ratings or view top-rated stocks.

6 Wall Street analysts have issued 12 month price targets for Sangamo Therapeutics' shares. Their SGMO share price forecasts range from $5.00 to $19.00. On average, they predict the company's stock price to reach $13.83 in the next twelve months. This suggests a possible upside of 733.3% from the stock's current price.
View analysts price targets for SGMO or view top-rated stocks among Wall Street analysts.

Sangamo Therapeutics' stock was trading at $3.14 at the beginning of 2023. Since then, SGMO shares have decreased by 47.1% and is now trading at $1.66.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 4th 2023.
View our SGMO earnings forecast.

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) issued its quarterly earnings data on Wednesday, February, 22nd. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, beating the consensus estimate of ($0.36) by $0.04. The biopharmaceutical company had revenue of $27.23 million for the quarter, compared to analysts' expectations of $26.86 million. Sangamo Therapeutics had a negative net margin of 172.76% and a negative trailing twelve-month return on equity of 61.19%. The business's revenue for the quarter was down 2.7% compared to the same quarter last year. During the same period last year, the company posted ($0.26) EPS.

ETFs with the largest weight of Sangamo Therapeutics (NASDAQ:SGMO) stock in their portfolio include Direxion mRNA ETF (MSGR), Kelly CRISPR & Gene Editing Technology ETF (XDNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Global X Genomics & Biotechnology ETF (GNOM), iShares Genomics Immunology and Healthcare ETF (IDNA), Invesco Nasdaq Future Gen 200 ETF (QQQS), WisdomTree BioRevolution Fund (WDNA) and SPDR S&P Biotech ETF (XBI).

10 employees have rated Sangamo Therapeutics Chief Executive Officer Sandy Macrae, M.B., Ch.B., Ph.D. on Glassdoor.com. Sandy Macrae, M.B., Ch.B., Ph.D. has an approval rating of 89% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), CRISPR Therapeutics (CRSP), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Editas Medicine (EDIT), Netflix (NFLX) and Intel (INTC).

Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO."

Sangamo Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Credit Suisse AG (2.32%), Dimensional Fund Advisors LP (2.10%), Avidity Partners Management LP (1.68%), Geode Capital Management LLC (1.52%), Renaissance Technologies LLC (1.29%) and JPMorgan Chase & Co. (0.95%). Insiders that own company stock include Biogen Inc, Gary Loeb, John Markels, Rolf Andrew Ramelmeier and Saira Ramasastry.
View institutional ownership trends.

Shares of SGMO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of SGMO stock can currently be purchased for approximately $1.66.

Sangamo Therapeutics (NASDAQ:SGMO) has a market capitalization of $279.68 million and generates $111.30 million in revenue each year. The biopharmaceutical company earns $-192,280,000.00 in net income (profit) each year or ($1.25) on an earnings per share basis.

The company employs 431 workers across the globe.

Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The official website for the company is www.sangamo.com. The biopharmaceutical company can be reached via phone at (510) 970-6000, via email at investor.relations@sangamo.com, or via fax at 510-236-8951.